Sandalwood giant can smell big dollars in warts more

ViroXis Corporation Announces expanded board of directors and advisors more

ITClamp Hemorrhage Control System from Innovative Trauma Care more

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. more

Innovative Trauma Care (ITC) has received regulatory approval from Health Canada for commercial sale of its first product, the IT Clamp™ more

SAN ANTONIO, SEPT. 7, 2012 — /PRNewswire/ -- BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding. The company worked closely with BiO2 Medical's investment bankers, Pasadera Capital for this Series C round. This funding will allow BiO2 Medical to commercialize the Angel™ Catheter. Remeditex Ventures, LLC led the round along with BiO2 Medical's existing investors.

Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer said, "We are thrilled to have Remeditex join on with BiO2 Medical, as they bring a tremendous amount of experience to the company. We are all looking forward to a successful launch of the Angel™ Catheter which will provide a valuable tool for providing PE prophylaxis in critically ill patients."

"We are excited to be part of the highly qualified BiO2 Medical team. BiO2 has developed a promising product that addresses a significant unmet medical need," said John Creecy, Chief Executive Officer and Director of Remeditex Ventures. "We believe the company is poised to become an important innovator, addressing the needs of patients by substantially reducing the risks associated with pulmonary embolism."

BiO2 Medical's Angel™ Catheter, named after its inventor and BiO2 Medical's Chief Medical Officer, Dr. Luis F. Angel, is a central venous catheter and Inferior Vena Cava (IVC) filter combination device, intended to protect against potentially fatal Pulmonary Embolism (PE) in critically ill patients. The Angel™ Catheter will include a first of its kind prophylactic indication for IVC filter use. For more information regarding BiO2 Medical and the Angel™ Catheter, please visit www.bio2medical.com back

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication more

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

BiO2 Medical Announces First in Man Clinical Study more

BiO2 Medical Secures Series B Round Funding more

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia more

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more